NAFLD/NASH: Towards a successful selection and profiling of your drug candidate
Number of drugs with different mechanism of actions is undergoing clinical trials for non-alcoholic steatohepatitis (NASH). Given the complexity of the disease with respect to pathophysiology in the liver and associated metabolic changes in the whole body, it becomes apparent that combined histo-molecular, cellular and functional analyses need to be put in place for a successful nomination and profiling of a drug candidate for NAFLD/NASH.
This webinar will offer new insights to address these preclinical challenges. When drug mechanism of action and efficacy associated biomarkers could vary in high and/or low steatosis areas contained on the same tissue section, this key biological information could easily be missed by global analyses. Dr Rima Ait-Belkacem (Imabiotech) and Laurent Benel, (Metabrain) will present the results of an extensive PK/PD study in HFD-mice using PIOGLITAZONE as a PPARγ agonist, stressing the elevated liver enzymes activity, drug efficacy and metabolic pathways with respect to the steatosis abundancy regions.
At the end of the webinar, the participant should:
– Get a better understanding of the high relevance of histo-molecular imaging methodology in pathophysiological animal models
– Be aware that new tools become available for NAFLD/NASH models validation for therapeutics efficacy evaluation
Tuesday, December 10, 2019
Two time slots:
USA at 12pm New York Time.
Europe at 5pm French Time.